POTASSIUM ACETATE

Post-LOE

potassium acetate

Fresenius Kabi

ANDAINJECTIONINJECTABLE

Approved

Nov 2024

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

POTASSIUM ACETATE (potassium acetate) by Fresenius Kabi is clinical pharmacology as the principal cation of the intracellular fluid, potassium plays an important role in fluid and electrolyte balance. First approved in 2024.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY As the principal cation of the intracellular fluid, potassium plays an important role in fluid and electrolyte balance. The normal potassium concentration in the intracellular fluid compartment is about 160 mEq/liter. The normal serum potassium range is 3.5 to 5.0 mEq/liter.…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Company

Worked on POTASSIUM ACETATE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.